Development of an Antimicrobial Susceptibility Test (AST) for the Antistaphylococcal Lysin CF-301 Presented at 27th ECCMID, April 22, 2017
Long Term Immunology Results of a Phase 1 Placebo Controlled Dose Escalating Study to Examine the Safety of CF-301 in Human Volunteers Presented at 27th ECCMID, April 22, 2017
Staphylococcus aureus Resistance to Lysin CF-301 Does Not Arise in Human Serum Oral Presentation at ASM Microbe 2016, June 20
Post-Antibiotic Effects of Lysin CF-301 Against Staphylococcus aureus in Human Serum Oral Presentation at ASM Microbe 2016, June 20
PK-PD Driver of Efficacy for CF-301, a Novel Anti-Staphylococcal Lysin: Implications for Human Target Dose Presented at ASM Microbe 2016, June 18
Results of the First In Human Study of Lysin CF-301 Evaluating the Safety, Tolerability and Pharmacokinetic Profile in Healthy Volunteers Presented at 26th ECCMID, April 9, 2016
Efficacy of Single-Dose Lysin CF-301 in Combination with Vancomycin (VAN) or Daptomycin (DAP) in Experimental Endocarditis (IE) Due to Methicillin-Resistant Staphylococcus aureus (MRSA) Oral Presentation at ICAAC 2014, September 9
CF-301, a Phage Lysin, is Superior in Combination Therapy to Antistaphylococcal Antibiotics Alone in Murine Staphylococcus aureus Bacteremia Presented at ICAAC 2013, September 11
CF-301, a Phage Lysin, is a Potent Antimicrobial Agent Against Staphylococcus aureus Presented at ICAAC 2013, September 11
CF-301, a Phage Lysin, Demonstrates Rapid Bactericidal and Synergistic Activity Against Staphylococcus aureus Presented at ICAAC 2013, September 11
